Volume 15, Issue 4 pp. 347-360
RESEARCH ARTICLE

Resveratrol benefits the lineage commitment of bone marrow mesenchymal stem cells into osteoblasts via miR-320c by targeting Runx2

Jilong Zou

Jilong Zou

Department of Orthopaedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Search for more papers by this author
Jianyang Du

Jianyang Du

Department of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

Search for more papers by this author
Hualei Tu

Hualei Tu

Department of Burn, The Fifth Hospital in Harbin, Harbin, China

Search for more papers by this author
Hongjun Chen

Hongjun Chen

Department of Orthopaedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Search for more papers by this author
Kai Cong

Kai Cong

Department of Orthopaedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Search for more papers by this author
Zhenggang Bi

Zhenggang Bi

Department of Orthopaedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Search for more papers by this author
Jiabing Sun

Corresponding Author

Jiabing Sun

Department of Orthopaedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China

Correspondence

Jiabing Sun, Department of Orthopaedics, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.

Email: [email protected]

Search for more papers by this author
First published: 22 January 2021
Citations: 14

Abstract

Bone marrow mesenchymal stem cells (BMSCs) are a potential source of osteoblasts and have been widely used in clinical therapies due to their pluripotency. Recent publications have found that resveratrol (RSVL) played a crucial role in the proliferation and differentiation of BMSCs; however, the underlying molecular mechanism of RSVL-induced BMSCs osteogenic differentiation needs to be fully elucidated. The objective of this study was to explore functions of miRNAs in the RSVL-treated BMSCs and its effects on the differentiation potentials of BMSCs. The findings demonstrated that RSVL enhanced the osteogenesis and suppressed the adipogenesis of BMSCs in a dose-dependent manner. Besides, a novel regulatory axis containing miR-320c, and its target Runx2 was found during the differentiation process of BMSCs under RSVL treatment. Increase of miR-320c reduced the osteogenic potential of BMSCs, while knockdown of miR-320c played a positive role in the osteogenesis of BMSCs. In contrast, overexpression of miR-320c accelerated the adipogenic differentiation, while knockdown of miR-320c restrained the adipogenic differentiation of BMSCs. The results confirmed that Runx2 might be the direct target of miR-320c in RSVL-promoted osteogenic differentiation of BMSCs. This study revealed that RSVL might be used for the treatment of bone loss related diseases and miR-320c could be regarded as a novel and potential target to regulate the biological functions of BMSCs.

CONFLICT OF INTEREST

The authors indicated no potential conflicts of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.